home / stock / gnpx / gnpx articles
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural F...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1.5% on Wednesday. The Dow traded down 0.21% to 38,384...
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter ...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial publi...
Genprex has had a wild success recently, at the 5th Annual Immuno-Oncology where it first presented the game-changing drug known as Oncoprex to find non-small lung cancer in the most effective and final fashion imaginable.
News, Short Squeeze, Breakout and More Instantly...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of...
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene ther...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in li...